Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) Operating Expenses (2021 - 2025)

Valion Bio has reported Operating Expenses over the past 5 years, most recently at $2.3 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 58.51% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $5.9 million, up 3.87%, while the annual FY2024 figure was $5.7 million, 33.63% down from the prior year.
  • Operating Expenses for Q3 2025 was $2.3 million at Valion Bio, up from $2.0 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $3.1 million in Q2 2022 and troughed at $1.0 million in Q2 2021.
  • A 5-year average of $1.9 million and a median of $2.0 million in 2025 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 207.53% in 2022 and later tumbled 44.69% in 2024.
  • Year by year, Operating Expenses stood at $2.3 million in 2021, then grew by 0.39% to $2.3 million in 2022, then decreased by 2.17% to $2.2 million in 2023, then tumbled by 44.69% to $1.2 million in 2024, then skyrocketed by 87.94% to $2.3 million in 2025.
  • Business Quant data shows Operating Expenses for TIVC at $2.3 million in Q3 2025, $2.0 million in Q2 2025, and $1.6 million in Q1 2025.